DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Litton J, Rugo H, Ettl J. et al.
Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
Cancer Res 2018;
78: GS6-07-GS06-07
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.